Notice Pursuant to the National Cooperative Research and Production Act of 1993-BioNanomatrix-Complete Genomics NIST ATP Joint Venture, 9356 [08-755]

Download as PDF 9356 Federal Register / Vol. 73, No. 34 / Wednesday, February 20, 2008 / Notices you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. We will make all submissions from organizations or businesses, from individuals identifying themselves as representatives or officials, or organizations or businesses available for public inspection in their entirety. Dated: August 24, 2007. Ernest Quintana, Regional Director, Midwest Region. EDITORIAL NOTE: This document was received at the Office of the Federal Register on February 14, 2008. [FR Doc. 08–763 Filed 2–19–08; 8:45 am] BILLING CODE 4312–AE–M Assistance to Individuals With Disabilities at the Public Meeting DEPARTMENT OF THE INTERIOR National Park Service rwilkins on PROD1PC63 with NOTICES Notice of Meeting of Concessions Management Advisory Board SUMMARY: In accordance with the Federal Advisory Committee Act (Public Law 92–463, 86 Stat. 770, 5 U.S.C. App 1, Section 10), notice is hereby given that the Concessions Management Advisory Board (the Board) will hold its 18th meeting March 12–13, 2008, at Embassy Suites Hotel, Washington, DC. The meeting will convene Wednesday, March 12 at 10 a.m. and will conclude at 4 p.m. The meeting will reconvene Thursday, March 13 at 9 a.m. and will conclude before 4 p.m. ADDRESSES: The meeting will be held in DC Convention Center Embassy Suites Hotel, 900 10th Street, NW., Washington, DC 20001. Hotel phone number: (202) 719–1438. SUPPLEMENTARY INFORMATION: The Board was established by Title IV, Section 409 of the National Parks Omnibus Management Act of 1998, November 13, 1998 (Pub. L. 105–391). The purpose of the Board is to advise the Secretary and the National Park Service on matters relating to management of concessions in the National Park System. The Board will meet at 10 a.m. Wednesday, March 12, and 9 a.m. on Thursday, March 13, for the regular business meeting and continued discussion on the following subjects: • Presentations by National Park Hospitality Association • Leasehold Surrender Interest Tracking Tool Update • Concession Contracting Status Update and Regional Reports • Revised Concession Annual Operational Review Forms VerDate Aug<31>2005 17:31 Feb 19, 2008 • Concession Facility Asset Management Update • DO 35B—Utility Rates for Non-NPS Users • Centennial Challenge Initiative Status • Concession Program Training and Development Update • Buy American Initiative • Other business The meeting will be open to the public, however, facilities and space for accommodating members of the public are limited, and persons will be accommodated on a first-come-firstserved basis. Jkt 214001 The meeting site is accessible to individuals with disabilities. If you plan to attend and will require an auxiliary aid or service to participate in the meeting (e.g., interpreting service, assistive listening device, or materials in an alternate format), notify the contact person listed in this notice at least 2 weeks before the scheduled meeting date. Attempts will be made to meet any request(s) we receive after that date, however, we may not be able to make the requested auxiliary aid or service available because of insufficient time to arrange for it. Anyone may file with the Board a written statement concerning matters to be discussed. The Board may also permit attendees to address the Board, but may restrict the length of the presentations as necessary to allow the Board to complete its agenda within the allotted time. Such requests should be made to the Director, National Park Service, Attention: Manager, Concession Program, at least 7 days prior to the meeting. Draft minutes of the meeting will be available for public inspection approximately 6 weeks after the meeting, at the Concession Program office located at 1201 Eye Street, NW., 11th Floor, Washington, DC. FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—BioNanomatrix-Complete Genomics NIST ATP Joint Venture Notice is hereby given that, on January 10, 2008 pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), BioNanomatrix-Complete Genomics NIST ATP Joint Venture has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the partes and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: BioNanomatrix, Inc., Philadelphia, PA; and Complete Genomics, Inc., Mountain View, CA. The general area of planned activity for BioNanomatrixComplete Genomics NIST ATP Joint Venture is to research the feasibility of sequencing the entire human genome in less than 8 hours for less than $100 using breakthrough technology called Linear Imaging Sequence Analysis (LISA) which requires the use of a novel sequence interrogation chemistry developed from CGI’s ligation sequencing chemistry combined with a novel nanofluidic biochip adapted from BNM’s nanoanalyzer technology. The activities of this venture project will be partially funded by an award from the Advanced Technology Program, National Institute of Standards and Technology, U.S. Department of Commerce under Award Number 70NANB7H7027. Patricia A. Brink, Deputy Director of Operations, Antitrust Division. [FR Doc. 08–755 Filed 2–19–08; 8:45 am] BILLING CODE 4140–11–M National Park Service, Concession Program, 1201 Eye Street, NW., Washington, DC 20240, Telephone: 202–13–7151. DEPARTMENT OF JUSTICE Dated: February 13, 2008. Daniel N. Wenk, Deputy Director, National Park Service. [FR Doc. E8–3132 Filed 2–19–08; 8:45 am] Notice Pursuant to the National Cooperative Research and Production Act of 1993—Electronic Healthcare Network Accreditation Commission BILLING CODE 4312–53–P Notice is hereby given that, on January 18, 2008, pursuant to Section PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 Antitrust Division E:\FR\FM\20FEN1.SGM 20FEN1

Agencies

[Federal Register Volume 73, Number 34 (Wednesday, February 20, 2008)]
[Notices]
[Page 9356]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-755]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--BioNanomatrix-Complete Genomics NIST ATP Joint 
Venture

    Notice is hereby given that, on January 10, 2008 pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), BioNanomatrix-Complete 
Genomics NIST ATP Joint Venture has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing (1) the identities of the partes and (2) the 
nature and objectives of the venture. The notifications were filed for 
the purpose of invoking the Act's provisions limiting the recovery of 
antitrust plaintiffs to actual damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture are: BioNanomatrix, Inc., Philadelphia, PA; and Complete 
Genomics, Inc., Mountain View, CA. The general area of planned activity 
for BioNanomatrix-Complete Genomics NIST ATP Joint Venture is to 
research the feasibility of sequencing the entire human genome in less 
than 8 hours for less than $100 using breakthrough technology called 
Linear Imaging Sequence Analysis (LISA) which requires the use of a 
novel sequence interrogation chemistry developed from CGI's ligation 
sequencing chemistry combined with a novel nanofluidic biochip adapted 
from BNM's nanoanalyzer technology.
    The activities of this venture project will be partially funded by 
an award from the Advanced Technology Program, National Institute of 
Standards and Technology, U.S. Department of Commerce under Award 
Number 70NANB7H7027.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. 08-755 Filed 2-19-08; 8:45 am]
BILLING CODE 4140-11-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.